Page 5 - Natco Pharma
Natco Pharma hits 52-week high on USFDA nod for generic Tamiflu
The stock rallied 7% to Rs 650 also its 52-week high on the National Stock Exchange in early morning trade.
 "Natco Pharma hits 52-week high on USFDA nod for generic Tamiflu")
Updated On : 04 Aug 2016 | 9:52 AM IST
Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets
The stock was trading higher by 4% to Rs 552, extending its Wednesday's 6% rally on the BSE
 "Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets")
Updated On : 23 Jun 2016 | 1:46 PM IST
Natco Pharma gains on tentative nod from USFDA for cancer drug
The stock up 9% to Rs 523 after the company said that its marketing partner, Mylan Inc., has received a US regulator tentative nod Sorafenib, the generic version of Nexavar.
 "Natco Pharma gains on tentative nod from USFDA for cancer drug")
Updated On : 03 Jun 2016 | 2:33 PM IST
Natco Pharma gains on sale of non-core business in US
The board approved the sale of Save Mart Pharmacy Stores located in USA which is non-core business
 "Natco Pharma gains on sale of non-core business in US")
Updated On : 31 Mar 2016 | 12:33 PM IST
US regulator looms over Natco prospects
Company says no impact on product pipeline but Street awaits more clarity
 "US regulator looms over Natco prospects")
Updated On : 28 Mar 2016 | 11:22 PM IST
Natco Pharma slips on USFDA observations
The stock slipped 11% to Rs 417 on the BSE in early morning trade.
Updated On : 28 Mar 2016 | 9:34 AM IST
USFDA observations on 2 units not to impact products: Natco
Natco Pharma Ltd has already sent response and compliance report for these observations
 "USFDA observations on 2 units not to impact products: Natco")
Updated On : 27 Mar 2016 | 7:19 PM IST
